DETERA Therapeutics, a peptide to prevent crescentic glomerulonephritis (CGN)
… SATT Paris-Saclay, which ensured its maturation, and in March 2025, the start-up signed a transfer agreement with … funding the following month. In June 2025, the start-up was selected by Bpifrance to join the deep tech community. … costs. Current treatments, which include dialysis, transplants and long-term hospitalisation, are costly for the …
Published on: